AISF practice guidance on the treatment of primary biliary cholangitis: A 2026 update.

What was studied

This is a 2026 update of AISF guidance on primary biliary cholangitis (PBC). PBC is a long-term autoimmune liver disease. If untreated, it may lead to scarring and liver problems. It covers treatment goals and how to judge response. It also covers second-line drugs. It covers care in cirrhosis, pregnancy, and other settings.

What they found

The abstract gives no study results. It says UDCA is still the cornerstone of first-line care. It says UDCA improves survival without a transplant. Some people still respond poorly. Many keep strong symptoms, mainly itching and fatigue. Obeticholic acid was withdrawn. Elafibranor and seladelpar are now available. Care now weighs blood tests, scarring stage, liver stiffness, and patient reports.

What it means for patients

The guidance says doctors can set goals for each patient. These depend on age, stage, symptoms, and risk. It tells apart adequate and complete response. It backs earlier step-up of treatment. This is for high-risk patients and those with symptoms. It stresses a patient-centred approach.

Why it is not certain yet

No trial data are given. It does not say how strong the evidence is. The authors name unmet needs. A guideline reflects the evidence and views available when written.

Source

AISF practice guidance on the treatment of primary biliary cholangitis: A 2026 update.

We restate facts from the source record in our own words. The original wording belongs to its publisher.